Vertex Pharmaceuticals (VRTX)
Company Profile
| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 4.95 bn | 4.95 bn | 4.95 bn | 4.95 bn | 4.95 bn | 4.95 bn |
| Cash burn (monthly) | 11.40 mm | 25.03 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 15.89 mm | 34.88 mm | n/a | n/a | n/a | n/a |
| Cash remaining | 4.93 bn | 4.91 bn | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 432.6 | 196.3 | n/a | n/a | n/a | n/a |
| 13F holders | Current |
|---|---|
| Total holders | 1524 |
| Opened positions | 197 |
| Closed positions | 195 |
| Increased positions | 543 |
| Reduced positions | 594 |
| 13F shares | Current |
|---|---|
| Total value | 90.14 tn |
| Total shares | 235.66 mm |
| Total puts | 1.44 mm |
| Total calls | 1.60 mm |
| Total put/call ratio | 0.9 |
| Largest owners | Shares | Value |
|---|---|---|
| Capital World Investors | 28.33 mm | $11.41 tn |
| Vanguard | 23.26 mm | $9.37 tn |
| BlackRock | 21.83 mm | $8.79 tn |
| STT State Street | 11.98 mm | $4.82 tn |
| Capital Research Global Investors | 10.43 mm | $4.20 tn |
| FMR | 9.22 mm | $3.71 tn |
| JPM JPMorgan Chase & Co. | 6.31 mm | $2.54 tn |
| Wellington Management | 5.92 mm | $2.38 tn |
| Geode Capital Management | 5.65 mm | $2.27 tn |
| Jennison Associates | 4.32 mm | $1.74 tn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Oct 25 | Sachs Bruce I | Deferred Stock Units Common Stock | Grant | Acquire A | No | No | 410.31 | 115.766 | 47.50 k | 15,457.433 |
| 15 Oct 25 | Upadhyay Suketu | Deferred Stock Units Common Stock | Grant | Acquire A | No | No | 410.31 | 86.825 | 35.63 k | 2,638.332 |
| 2 Oct 25 | Biller Jonathan | Common Stock | Sell | Dispose S | No | Yes | 404.21 | 694 | 280.52 k | 15,653 |
| 1 Oct 25 | Biller Jonathan | Common Stock | Payment of exercise | Dispose F | No | No | 400 | 1,259 | 503.60 k | 16,347 |
| 27 Aug 25 | Bhatia Sangeeta N. | Common Stock | Sell | Dispose S | No | Yes | 386.69 | 266 | 102.86 k | 4,565 |
| 6 Aug 25 | Kewalramani Reshma | Common Stock | Buy | Acquire P | No | No | 389.95 | 5,710 | 2.23 mm | 115,968 |
| 6 Aug 25 | Kewalramani Reshma | Common Stock | Buy | Acquire P | No | No | 389.08 | 4,290 | 1.67 mm | 110,258 |